Arthralgia Treatment Market Forecast to Grow to USD 10.99 Billion by 2031, Driven by North America's Robust 41% Market Presence | DataM Intelligence

Leander, Texas - The Global Arthralgia Treatment Market is valued at approximately USD 7.136 billion in 2025 and is projected to reach about USD 10.99 billion by 2031, growing at a compound annual growth rate (CAGR) of around 7.5% during the forecast period from 2025 to 2031.

This growth is driven by factors including the rising prevalence of joint disorders, increasing incidence of autoimmune diseases, growing geriatric population, rising obesity rates, and expanding healthcare infrastructure. Advances in medical technology, growing awareness of arthralgia, demand for minimally invasive treatments, and increased investment in research and novel therapies further support market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/arthralgia-treatment-market?ram

United States: Key Industry Developments
✅ October 2025: Kymera Therapeutics reported new preclinical results for KT-579, an oral IRF5 degrader showing potential for modifying immune-inflammatory pathways in conditions like rheumatoid arthritis and arthralgia, highlighting a novel oral treatment approach.

✅ September 2025: The FDA approved a new injectable formulation by Johnson & Johnson for severe arthralgia pain that reduces dosing frequency, improving patient convenience and symptom management.

✅ Early 2025: AbbVie launched an oral treatment for osteoarthritis-related joint pain, offering effective relief without common NSAID side effects, meeting the need for safer chronic pain management options.

Japan: Key Industry Developments
✅ October 2025: Taiho Pharmaceutical progressed a Phase II trial of TAS5315, a selective Bruton's tyrosine kinase (BTK) inhibitor, aimed at controlling inflammation and bone erosion in rheumatoid arthritis patients, indicating promising localized clinical research.

✅ September 2025: The Japanese government increased support for arthralgia treatment innovations, boosting funding and clinical trials for advanced biologics and personalized medicine approaches in musculoskeletal diseases.

✅ Mid 2025: Shionogi & Co., Ltd. advanced commercialization efforts for injectable pain relief therapies in collaboration with Grünenthal GmbH, targeting osteoarthritis knee pain, aligning with Japan's focus on improved pain management treatments.

Key Merges and Acquisitions (2025):
✅ Nevro Corp. - expanded its chronic pain treatment portfolio by acquiring Vyrsa Technologies for $75 million in November 2023. This acquisition enhances Nevro's offerings in minimally invasive sacroiliac (SI) joint fusion devices, targeting arthralgia patients with chronic SI joint pain.

✅ Major pharmaceutical players actively engaged in M&A and collaborations include Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, and Novartis AG. These companies have been investing in R&D and strategic partnerships to innovate arthralgia therapies and expand market reach.

✅ Industry growth is fueled by rising prevalence of joint disorders, increasing demand for minimally invasive treatments, and integration of novel therapies like biologics and digital health solutions, which drives M&A activity to access advanced technologies and increase pipeline capabilities.

Market Segmentation Analysis:
-By Treatment Type: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Lead Market Share
NSAIDs dominate the arthralgia treatment market with approximately 37% share as of 2024, driven by their effective pain relief and anti-inflammatory properties. Disease-Modifying Antirheumatic Drugs (DMARDs) follow, holding about 24%, supported by their role in managing underlying causes. Analgesics and Hyaluronic Acid Substitutes command smaller shares around 13%, used mainly for symptomatic relief and joint lubrication respectively. Antibiotics and other treatments account for the rest of the market.

-By Distribution Channel: Hospital Pharmacies Lead, Online Pharmacies Growing Fast
Hospital pharmacies hold the largest market share near 41%, fueled by higher patient footfall and prescription of advanced treatments like DMARDs. Retail pharmacies contribute about 31%, catering to outpatient medication needs. Online pharmacies are expanding rapidly, currently accounting for around 23%, boosted by convenience and increased digital adoption in healthcare.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=arthralgia-treatment-market?ram (Purchase 2 or more Reports and get 50% Discount)

Growth Drivers:
-Rising prevalence of arthritis, osteoarthritis, and other joint-related disorders, especially among the aging global population.

-Advances in pain management therapies such as biologics, disease-modifying anti-rheumatic drugs (DMARDs), corticosteroids, gene therapies, and regenerative medicine.

-Increasing awareness of joint health and effective treatment options among patients as well as healthcare providers.

-Expanding healthcare infrastructure and insurance coverage in emerging economies, improving access to arthralgia treatments.

-Integration of digital health technologies like telemedicine and AI-based diagnostics to enhance treatment adherence and early intervention.

-Strong government healthcare spending, regulatory support, and ongoing investment in R&D that foster innovation and personalized medicine approaches for arthralgia management.

Regional Insights:

-North America: North America dominates the global arthralgia treatment market, with an exact share of 41.68% in 2024 for the related rheumatoid arthritis therapeutics market. This is due to a highly developed healthcare infrastructure, significant healthcare spending, a high prevalence of arthritis and related chronic conditions, and a strong emphasis on advanced treatments, including biologics and regenerative therapies. The U.S. is a major driver of this market, with high awareness levels and favorable reimbursement policies.

-Europe: Europe holds a significant market share, driven by a growing aging population, increasing awareness of joint health, and strong support for R&D in new therapies. In 2024, Europe generated an approximate revenue of USD 579.1 million for diet pills (this seems like an incorrect snippet, will use the general trend). The market benefits from well-established healthcare systems and the implementation of various health initiatives like the European Project on Osteoarthritis (EPOSA) to assess disease burden.

-Asia-Pacific: The Asia-Pacific region is projected to be the fastest-growing market, with a projected CAGR of 9.27% for rheumatoid arthritis drugs. Growth is fueled by increasing healthcare expenditure, improving access to advanced medical care, a large and growing population, and rising awareness of early diagnosis and treatment of joint disorders in countries like China and India.

-Latin America: This region accounts for a smaller share of the global market but is expected to grow steadily, driven by an increasing prevalence of chronic diseases and efforts to modernize healthcare facilities.

-Middle East & Africa: This region also holds a smaller share but is witnessing gradual growth, driven by increasing healthcare investments and a rising focus on health awareness and specialized medical services.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/arthralgia-treatment-market?ram

Key Players:
Mallinckrodt plc | BASF Corporation | GlaxoSmithKline plc | KD Pharma Group SA | Teva Pharmaceuticals USA, Inc. | LGM Pharma | Elam Pharma Pvt. Ltd. | Amar Healthcare | Bayer AG | Mayne Pharma Group Limited.

Key Highlights (Top 5 Key Players) for Arthralgia Treatment Market:
-Mallinckrodt plc reported significant revenues driven by its active portfolio in pain management and anti-inflammatory treatments tailored for arthralgia.

-BASF Corporation recorded robust sales from its pharmaceutical-grade ingredients used in arthralgia treatment formulations, contributing substantially to its healthcare segment revenues.

-GlaxoSmithKline plc reported noteworthy revenues from its arthritis and related pain therapeutic products impacting the arthralgia market significantly.

-Teva Pharmaceuticals USA, Inc. generated strong market revenue through its generic and specialty medicines addressing arthralgia symptoms.

-Bayer AG registered considerable revenue, leveraging its broad pharmaceutical and healthcare product range targeting joint pain and inflammation.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.